Endogenous opioids contribute to the feeling of pain relief in humans

Downloads

[1] Allen M, Poggiali D, Whitaker K, Marshall TR, Kievit RA. Raincloud plots: a multi-platform tool for robust data visualization. Wellcome Open Res 2019;4:63. [2] Anderson WS, Sheth RN, Bencherif B, Frost JJ, Campbell JN. Naloxone increases pain induced by topical capsaicin in healthy human volunteers. PAIN 2002;99:207–16. [3] Appelhans B, Luecken L. Heart rate variability as an index of regulated emotional responding. Rev Gen Psychol 2006;10:229–40. [4] Barr DJ, Levy R, Scheepers C, Tily HJ. Random effects structure for confirmatory hypothesis testing: keep it maximal. J Mem Lang 2013;68: 255–78. [5] Bayarri MJ, Garc´ıa-Donato G. Extending conventional priors for testing general hypotheses in linear models. Biometrika 2007;94:135–52. [6] Becker S, Kleinbohl D, Klossika I, Holzl R. Operant conditioning of enhanced pain sensitivity by heat-pain titration. PAIN 2008;140:104–14. [7] Becker S, Kleinbohl D, Baus D, Holzl R. Operant learning of perceptual sensitization and habituation is impaired in fibromyalgia patients with and without irritable bowel syndrome. PAIN 2011;152:1408–17. [8] Becker S, Fuchs X, Schakib-Ekbatan K, Schweiker M. What does “moderate pain” mean? Subgroups holding different conceptions of rating scales evaluate experimental pain differently. Eur J Pain 2020;24: 625–38. [9] Belsley DA, Kuh E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: Wiley, 1980. [10] Benedek M, Kaernbach C. A continuous measure of phasic electrodermal activity. J Neurosci Methods 2010;190:80–91. [11] Berna C, Leknes S, Ahmad AH, Mhuircheartaigh RN, Goodwin GM, Tracey I. Opioid-independent and opioid-mediated modes of pain modulation. J Neurosci 2018;38:9047–58. [12] Bodnar RJ. Endogenous Opiates and behavior: 2018. Peptides 2020; 132:170348. [13] Bromm B, Scharein E. Response plasticity of pain evoked reactions in man. Physiol Behav 1982;28:109–16. [14] Cabanac M. Sensory pleasure. Q Rev Biol 1979;54:1–29. [15] Castro DC, Berridge KC. Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness liking and wanting. J Neurosci 2014;34:4239–50. [16] Eikemo M, Loseth GE, Johnstone T, Gjerstad J, Willoch F, Leknes S. Sweet taste pleasantness is modulated by morphine and naltrexone. Psychopharmacology (Berl) 2016;233:3711–23. [17] Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, Buchel C. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009;63:533–43. [18] Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL III. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009;10:447–85. [19] Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976;39:1071–5. [20] Gard D, Germans Gard M, Kring A, John O. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J Res Personal 2006;40:1086–102. [21] Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35: 192–213. [22] Hayano J, Sakakibara Y, Yamada A, Yamada M, Mukai S, Fujinami T, Yokoyama K,Watanabe Y, Takata K. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol 1991; 67:199–204. [23] Holzl R, Kleinbohl D, Huse E. Implicit operant learning of pain sensitization. PAIN 2005;115:12–20. [24] Jeffreys H. Theory of probability. Oxford: Clarendon Press, 1961. [25] Kas MJ, van den Bos R, Baars AM, Lubbers M, Lesscher HM, Hillebrand JJ, Schuller AG, Pintar JE, Spruijt BM. Mu-opioid receptor knockoutmice show diminished food-anticipatory activity. Eur J Neurosci 2004;20: 1624–32. [26] King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, Fields HL, Porreca F. Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci 2009;12:1364–6. [27] Koob GF, LeMoal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3113–23. [28] Lee MD, Wagenmakers E-J. Bayesian cognitive modeling: A practical course. New York: Cambridge University Press, 2013. [29] Leknes S, Brooks JC, Wiech K, Tracey I. Pain relief as an opponent process: a psychophysical investigation. Eur J Neurosci 2008;28: 794–801. [30] Leknes S, Berna C, Lee MC, Snyder GD, Biele G, Tracey I. The importance of context: when relative relief renders pain pleasant. PAIN 2013;154:402–10. [31] Loggia ML,Mogil JS, BushnellMC. Experimentally inducedmood changes preferentially affect pain unpleasantness. J Pain 2008;9:784–91. [32] Lorr M, Heuchert JW, McNair DM. Profile of Mood States: Bipolar Form. North Tonawanda: Multi-Health Systems (MHS), 2003. [33] Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82–9. [34] Ly A, Verhagen AJ, Wagenmakers EJ. Harold Jeffreys’s default Bayes factor hypothesis tests: explanation, extension, and application in psychology. J Math Psychol 2015;72:19–32. [35] McGraw K, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods 1996;1:30–46. [36] Mohr C, Leyendecker S, Mangels I, Machner B, Sander T, Helmchen C. Central representation of cold-evoked pain relief in capsaicin induced pain: an event-related fMRI study. PAIN 2008;139:416–30. [37] Mueller C, Klega A, Buchholz HG, Rolke R, Magerl W, Schirrmacher R, Schirrmacher E, Birklein F, Treede RD, Schreckenberger M. Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study. Neuroimage 2010;49:731–7. [38] Navratilova E, Xie JY, Okun A, Qu C, Eyde N, Ci S, Ossipov MH, King T, Fields HL, Porreca F. Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. Proc Natl Acad Sci U S A 2012;109:20709–13. [39] Navratilova E, Xie JY, Meske D, Qu C, Morimura K, Okun A, Arakawa N, Ossipov M, Fields HL, Porreca F. Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain. J Neurosci 2015;35: 7264–71. [40] Papaleo F, Kieffer BL, Tabarin A, Contarino A. Decreased motivation to eat in mu-opioid receptor-deficient mice. Eur J Neurosci 2007;25: 3398–405. [41] Pratt JW. Remarks on zeros and ties in the Wilcoxon signed rank procedures. J Am Stat Assoc 1959;54:655–67. [42] Price RC, Christou NV, Backman SB, Stone L, Schweinhardt P. Opioidreceptor antagonism increases pain and decreases pleasure in obese and non-obese individuals. Psychopharmacology (Berl) 2016;233: 3869–79. [43] Pulvers K, Hood A. The role of positive traits and pain catastrophizing in pain perception. Curr Pain Headache Rep 2013;17:330. [44] Rhudy JL, Bartley EJ, Williams AE. Habituation, sensitization, and emotional valence modulation of pain responses. PAIN 2010;148:320–7. [45] Rights JD, Sterba SK. Quantifying explained variance in multilevel models: an integrative framework for defining R-squared measures. Psychol Methods 2019;24:309–38. [46] Rouder JN, Morey RD. Default Bayes factors for model selection in regression. Multivariate Behav Res 2012;47:877–903. [47] Saeki Y. Effect of local application of cold or heat for relief of pricking pain. Nurs Health Sci 2002;4:97–105. [48] Schestatsky P, Valls-Sole J, Costa J, Leon L, Veciana M, Chaves ML. Skin autonomic reactivity to thermoalgesic stimuli. Clin Auton Res 2007; 17:349–55. [49] Seymour B, O’Doherty JP, Koltzenburg M, Wiech K, Frackowiak R, Friston K, Dolan R. Opponent appetitive-aversive neural processes underlie predictive learning of pain relief. Nat Neurosci 2005;8: 1234–40. [50] Smith KS, Berridge KC. The ventral pallidum and hedonic reward: neurochemical maps of sucrose liking and food intake. J Neurosci 2005; 25:8637–49. [51] Solomon RL, Corbit JD. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol Rev 1974;81:119–45. [52] Sullivan MJL, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32. [53] Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17:354–81. [54] Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 2007;321:544–52. [55] Werner MU, Pereira MP, Andersen LP, Dahl JB. Endogenous opioid antagonism in physiological experimental pain models: a systematic review. PLoS One 2015;10:e0125887. [56] Willoughby SG, Hailey BJ, Mulkana S, Rowe J. The effect of laboratoryinduced depressed mood state on responses to pain. Behav Med 2002; 28:23–31. [57] Yeomans MR, Gray RW. Selective effects of naltrexone on food pleasantness and intake. Physiol Behav 1996;60:439–46.